Quantification of radiopharmkon concentration within the scitigraphis diagnostic via SPECT/CT (QRCS-1): a prospective data acquisition within clinical indicated examinations

Recruiting

• Conditions: C61; C78.7; Malignant neoplasm of prostate; Secondary malignant neoplasm of liver and intrahepatic bile duct

• Registration Number: DRKS00013571
• Lead Sponsor: Radiologische UniversitätsklinikAbteilung für Nuklearmedizin und Klinische Molekulare Bildgebung

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 2018-01-25
• Study Start: 2018-02-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

indication for SPECT/CT examination

Exclusion Criteria

pregnancy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival over a period of 3 years<br>Aims of the study:<br>•Correlation of the radiotracer accumulation with manifestation of the disease in patients treated at the Department of Nuclearmedicine (i.g. SIRT in liver tumors, radionuclide therapy of osseous metastases in prostate cancer). In addition correlations with outcome of therapy and potential side effects will be investigated.<br>•Influence of segmentation parameters of (CT-information, NM-image, Threshholds) on measured activity and distribution volume<br>•Comparison of the results of phantom measurements in variation of Target-Background-ratio, lesion size and simulated tissue attenuation<br>•Comparison with established semiquantitative analyses of the tracer uptake (i.g. Shunt assessment in SIRT simulation)<br>

Secondary Outcome Measures

Name	Time	Method
Progression-free survival over a period of 3 years